- Home
- SWK vs BBIO Comparison
SWK vs BBIO Comparison
Compare SWK & BBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SWK
- BBIO
- Stock Information
- Founded
- SWK 1843
- BBIO 2015
- Country
- SWK United States
- BBIO United States
- Employees
- SWK N/A
- BBIO N/A
- Industry
- SWK Industrial Machinery/Components
- BBIO Biotechnology: Pharmaceutical Preparations
- Sector
- SWK Consumer Discretionary
- BBIO Health Care
- Exchange
- SWK Nasdaq
- BBIO Nasdaq
- Market Cap
- SWK 11.4B
- BBIO 9.4B
- IPO Year
- SWK N/A
- BBIO 2019
- Fundamental
- Price
- SWK $74.37
- BBIO $54.61
- Analyst Decision
- SWK Buy
- BBIO Strong Buy
- Analyst Count
- SWK 10
- BBIO 16
- Target Price
- SWK $93.89
- BBIO $64.44
- AVG Volume (30 Days)
- SWK 1.9M
- BBIO 2.1M
- Earning Date
- SWK 11-04-2025
- BBIO 11-11-2025
- Dividend Yield
- SWK 4.46%
- BBIO N/A
- EPS Growth
- SWK N/A
- BBIO N/A
- EPS
- SWK 3.16
- BBIO N/A
- Revenue
- SWK $15,161,600,000.00
- BBIO $235,812,000.00
- Revenue This Year
- SWK $0.42
- BBIO $115.97
- Revenue Next Year
- SWK $4.02
- BBIO $65.50
- P/E Ratio
- SWK $23.54
- BBIO N/A
- Revenue Growth
- SWK N/A
- BBIO 7.62
- 52 Week Low
- SWK $53.91
- BBIO $21.72
- 52 Week High
- SWK $109.91
- BBIO $54.60
- Technical
- Relative Strength Index (RSI)
- SWK 47.65
- BBIO 62.00
- Support Level
- SWK $72.55
- BBIO $51.85
- Resistance Level
- SWK $75.97
- BBIO $53.81
- Average True Range (ATR)
- SWK 1.93
- BBIO 1.66
- MACD
- SWK -0.32
- BBIO 0.15
- Stochastic Oscillator
- SWK 20.47
- BBIO 99.49
About SWK Stanley Black & Decker Inc.
Stanley Black & Decker Inc is a manufacturer of hand and power tools. The company operates in two reportable segments namely Tools and Outdoor and Industrial. It generates maximum revenue from the Tools and Outdoor segment. The Tools and Outdoor segment is comprised of the Power Tools Group (PTG), Hand Tools, Accessories and Storage (HTAS), and Outdoor Power Equipment (Outdoor) businesses. Geographically, the company generates revenue from the United States, Canada, Other Americas, Europe, and Asia. It derives a majority of its revenue from the United States.
About BBIO BridgeBio Pharma Inc.
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis) , is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.